**Table, Supplemental Digital Content 1:**

Analysis of IFX-TL versus same time-point clinical and biomarker activity status

|  |  |  |  |
| --- | --- | --- | --- |
|  | Disease status | Median IFX-TL µg/ml (IQR) | P value |
| Maintenance IFX-TL | Clinical Remission | 4.00 (3.7-4.39) | **<0.0001** |
| Clinically active disease | 2.25 (1.7-2.79) |
| Normal CRP | 3.3 (2.8-3.85) | **0.02** |
| Elevated CRP | 2.7 (2.2-3.6) |
| IFX-TL throughout therapy \* | Clinical Remission | 4.3 (3.9-4.6) | **<0.0001** |
| Clinically active disease | 2.5 (1.92-3.0) |
| Normal CRP | 3.8 (3.2-4.37) | **0.007** |
| Elevated CRP | 2.79 (2.4-3.7) |

\* Throughout therapy - both during induction and maintenance

IFX-TL- Infliximab trough level, CRP – C-reactive protein